Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 11/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.67 |
| ▸ | FYN | P06241 | 1/20 | 0.67 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.67 |
| ▸ | SRC | P12931 | 1/20 | 0.67 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.67 |
| ▸ | FLT1 | P17948 | 1/20 | 0.67 |
| ▸ | FLT4 | P35916 | 1/20 | 0.67 |
| ▸ | KDR | P35968 | 1/20 | 0.67 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.67 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.67 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.67 |
| ▸ | GSK3A | P49840 | 1/20 | 0.67 |
| ▸ | GSK3B | P49841 | 1/20 | 0.67 |
| ▸ | CDK7 | P50613 | 1/20 | 0.67 |
| ▸ | CSNK1G2 | P78368 | 1/20 | 0.67 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.67 |
| ▸ | CHEK1 | O14757 | 9/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3083785 | 0.99 | PDGFRB (0.66) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4043738 | 0.94 | PDGFRB (0.59) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4048239 | 0.93 | PDGFRB (0.58) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4047952 | 0.92 | PDGFRB (0.57) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4043150 | 0.92 | PDGFRB (0.57) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4049508 | 0.91 | PDGFRB (0.57) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4040259 | 0.90 | PDGFRB (0.56) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4046881 | 0.90 | PDGFRB (0.56) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4041471 | 0.90 | PDGFRB (0.56) | PDGFRBABL1LCKFYNFGFR1 | |
| SCHEMBL4043099 | 0.89 | CHEK1 (0.53) | PDGFRBABL1LCKFYNFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | claimed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | claimed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | claimed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | claimed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | claimed |
| US-20240150368-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-05-09 | — | — | US | claimed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | claimed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | claimed |
| CN-114634908-A | Direct reprogramming of human somatic cells into selected (predetermined) differentiated cells using functionalized nanoparticles | 斯特姆詹尼克斯公司 | 2022-06-17 | — | — | CN | claimed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | claimed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | claimed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | claimed |
| EP-2037954-A2 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | Janssen Pharmaceutica, N.V. (BE) | 2009-03-25 | — | — | EP | claimed |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-07 | — | — | US | claimed |
| WO-2007149827-A2 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-27 | — | — | WO | claimed |
| CN-1668601-A | N-substituted tricyclic 3-aminopyrazoles as PDFG receptor inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-14 | — | — | CN | claimed |
| EP-1506175-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-02-16 | — | — | EP | claimed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | claimed |
| WO-2003097609-A1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDFG RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-27 | — | — | WO | claimed |
| EP-3784232-B1 | IMPROVED METHODS FOR INDUCING TISSUE REGENERATION AND SENOLYSIS IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SCIPHER MEDICINE CORP (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250368949-A1 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2025-12-04 | — | — | US | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-4581014-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4580626-A1 | COMBINATION OF DCC-3116 AND MAPKAP PATHWAY INHIBITORS FOR USE IN THE TREATMENT OF CANCER | Deciphera Pharmaceuticals, LLC (US) | 2025-07-09 | — | — | EP | disclosed |
| EP-4578459-A1 | PHARMACEUTICAL PRODUCT FOR TREATMENT AND/OR PREVENTION OF CANCER | Toray Industries, Inc. (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-12325866-B2 | Systems and methods for growing cells in vitro | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-06-10 | — | — | US | disclosed |
| WO-2025106671-A1 | PERSONALIZED PROGENITOR CELLS | IMMORTA BIO, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12281117-B2 | Small molecule immune agonists and immune targeting compounds and application thereof | SHENZHEN UNIVERSITY (CN) | 2025-04-22 | — | — | US | disclosed |
| CN-119744176-A | Medicine for treating and/or preventing cancer | 东丽株式会社 | 2025-04-01 | — | — | CN | disclosed |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-27 | — | — | US | disclosed |
| US-20250084367-A1 | SYSTEMS AND METHODS FOR GROWING CELLS IN VITRO | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2025-03-13 | — | — | US | disclosed |
| EP-4460314-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240350553-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | AGEX THERAPEUTICS INC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4430047-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| EP-4419909-A1 | 3D CANCER CELLS | University of Sunderland (GB) | 2024-08-28 | — | — | EP | disclosed |
| EP-4415743-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | Reverse Bioengineering, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| CN-118475580-A | Platelet-derived growth factor receptor (PDGFR) alpha inhibitors and uses thereof | 普罗根托斯治疗公司 | 2024-08-09 | — | — | CN | disclosed |
| US-12036218-B2 | Modulators of airway basal cells for the treatment or prevention of lung diseases | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e. V. (DE) | 2024-07-16 | — | — | US | disclosed |
| US-20240203555-A1 | METHODS AND SYSTEMS FOR THERAPY MONITORING AND TRIAL DESIGN | SCIPHER MEDICINE CORP (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240180923-A1 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | DECIPHERA PHARMACEUTICALS, LLC | 2024-06-06 | — | — | US | disclosed |
| US-20240182864-A1 | NOVEL CHEMICAL COMBINATIONS AND METHODS OF USE THEREOF, TOWARDS DIFFERENTIATION OF HUMAN PROGENITOR CELLS INTO FUNCTIONAL BETA CELLS | SALK INSTITUTE FOR BIOLOGICAL STUDIES | 2024-06-06 | — | — | US | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| US-20240153580-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | Scipher Medicine Corporation | 2024-05-09 | — | — | US | disclosed |
| US-20240150368-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2024-05-09 | — | — | US | disclosed |
| WO-2024050351-A1 | COMBINATION OF DCC-3116 AND MAPKAP PATHWAY INHIBITORS FOR USE IN THE TREATMENT OF CANCER | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024043258-A1 | PHARMACEUTICAL PRODUCT FOR TREATMENT AND/OR PREVENTION OF CANCER | 東レ株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | JUNO THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4218748-A2 | BMP-MIMETICS | Christian-Albrechts-Universität zu Kiel (DE) | 2023-08-02 | — | — | EP | disclosed |
| WO-2023130150-A2 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023081923-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | Frequency Therapeutics, Inc. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023067352-A1 | 3D CANCER CELLS | UNIVERSITY OF SUNDERLAND (GB) | 2023-04-27 | — | — | WO | disclosed |
| WO-2023064577-A1 | METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLS | AGEX THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| EP-3675844-B1 | BMP-MIMETICS | UNIV KIEL CHRISTIAN ALBRECHTS (DE) | 2023-03-08 | — | — | EP | disclosed |
| US-11590167-B2 | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors | Juno Therapeutic, Inc. (US) | 2023-02-28 | — | — | US | disclosed |
| WO-2022165185-A9 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| US-20220288207-A1 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022165185-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
| WO-2022159687-A1 | PHENOTYPIC ASSAY TO IDENTIFY PROTEIN DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-11384150-B2 | Antibody-drug conjugates and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2022-07-12 | — | — | US | disclosed |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | Frequency Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| CN-108379591-B | Synthesis of immune agonist targeting compound and application thereof | 深圳大学 | 2022-03-29 | — | — | CN | disclosed |
| EP-3964214-A1 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-09 | — | — | EP | disclosed |
| US-20220062269-A1 | MODULATORS OF AIRWAY BASAL CELLS FOR THE TREATMENT OR PREVENTION OF LUNG DISEASES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-03-03 | — | — | US | disclosed |
| US-9982231-B2 | Methods for reprogramming differentiated non-cardiac cells into cardiomyocytes | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2018-05-29 | — | — | US | disclosed |
| US-9730926-B2 | Combination therapy using bispecific anti-c-Met/anti-EGFR antibody and c-Src inhibitor | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20160250260-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-01 | — | — | US | disclosed |
| EP-3043822-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-20 | — | — | EP | disclosed |
| EP-3039126-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone (US) | 2016-07-06 | — | — | EP | disclosed |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | 2016-06-30 | — | — | US | disclosed |
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-08-06 | — | — | US | disclosed |
| WO-2015041809-A2 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE NEURONAL CELLS | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015038704-A1 | COMPOSITIONS FOR PREPARING CARDIOMYOCYTES | THE J. DAVID GLADSTONE INSTITUTES, A TESTAMENTARY TRUST ESTABLISHED UNDER THE WILL OF J. DAVID GLADSTONE (US) | 2015-03-19 | — | — | WO | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| EP-2037954-A2 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | Janssen Pharmaceutica, N.V. (BE) | 2009-03-25 | — | — | EP | disclosed |
| CN-100396670-C | N-substituted 3-aminobenzene-pyrazoles as PDFG receptor inhibitors, pharmaceutical compositions and uses | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-25 | — | — | CN | disclosed |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-07 | — | — | US | disclosed |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-07 | — | — | US | disclosed |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-07 | — | — | US | disclosed |
| WO-2007149827-A2 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007149827-A2 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-12-27 | — | — | WO | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| CN-1668601-A | N-substituted tricyclic 3-aminopyrazoles as PDFG receptor inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-14 | — | — | CN | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (17 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150216972-A1 | COMBINATION THERAPY USING BISPECIFIC ANTI-C-MET/ANTI-EGFR ANTIBODY AND C-SRC INHIBITOR | SRC, MET, EGFR | PDGFRB 43/4885ABL1 13/4885LCK 14/4885 |
| US-20240016840-A1 | METHODS AND COMPOSITIONS FOR USE OF THERAPEUTIC T CELLS IN COMBINATION WITH KINASE INHIBITORS | ITK, PBK, BMX | PDGFRB 671/4885ABL1 39/4885LCK 15/4885 |
| US-20250099508-A1 | SYSTEMS, CELL LINES AND METHODS OF PRODUCING AND USING THE SAME | DCX, SLC10A2, CHAT | PDGFRB 1721/4885ABL1 3404/4885LCK 3952/4885 |
| US-12281117-B2 | Small molecule immune agonists and immune targeting compounds and application thereof | IFNG, IFNAR1, STING1 | PDGFRB 346/4885ABL1 2017/4885LCK 334/4885 |
| US-20160186141-A1 | SMALL MOLECULE CELLULAR REPROGRAMMING TO GENERATE CARDIOMYOCYTES | MYLK2, TNNI3, TNNT2 | PDGFRB 739/4885ABL1 1418/4885LCK 3011/4885 |
| US-20230364243-A1 | CANCER-SELECTIVE TARGET DEGRADATION BY TARGETING GROUP CAGED PROTACS | ADRM1, MYC, SKP2 | PDGFRB 1496/4885ABL1 1934/4885LCK 996/4885 |
| US-20080031866-A1 | METHOD FOR MODULATING THE PHARMACOKINETICS AND METABOLISM OF A THERAPEUTIC AGENT | OAT, GLS2, G6PD | PDGFRB 2964/4885ABL1 1866/4885LCK 3206/4885 |
| US-20220288207-A1 | PHOTO INDUCED CONTROL OF PROTEIN DESTRUCTION | UBE3C, PSMC1, UBE3A | PDGFRB 3698/4885ABL1 1941/4885LCK 4105/4885 |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | PDGFRB 2/4885ABL1 13/4885LCK 200/4885 |
| US-20040082639-A1 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | PDGFRB 2/4885ABL1 13/4885LCK 189/4885 |
| US-20260024617-A1 | METHODS AND SYSTEMS FOR PERSONALIZED THERAPIES | SET, SSB, CNKSR1 | PDGFRB 3263/4885ABL1 3176/4885LCK 2191/4885 |
| US-11590167-B2 | Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors | ITK, PBK, BMX | PDGFRB 574/4885ABL1 29/4885LCK 20/4885 |
| US-11384150-B2 | Antibody-drug conjugates and uses thereof | EGFR, ERBB2, ERBB3 | PDGFRB 105/4885ABL1 5/4885LCK 31/4885 |
| US-20240150368-A1 | ULK INHIBITORS AND METHODS OF USE THEREOF | ULK1, ULK2, ULK3 | PDGFRB 1998/4885ABL1 848/4885LCK 2749/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | PDGFRB 1/4885ABL1 58/4885LCK 295/4885 |
| US-20240180923-A1 | METHODS OF TREATING DISORDERS WITH ULK INHIBITORS | ULK1, ULK2, ULK3 | PDGFRB 3185/4885ABL1 733/4885LCK 2360/4885 |
| US-20220192984-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING OTIC THERAPEUTIC AGENTS AND RELATED METHODS | OTC, EXOSC5, ENTPD5 | PDGFRB 4382/4885ABL1 4228/4885LCK 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.